In an attempt to improve tumour uptake, substituents on the tertiary amine and triazole were 127 varied because altering the size of the amine and arene are known to impact melanin binding in 128
vivo.
22, 23 Compound 7b was synthesized by adding an aromatic group in the 5 position on the 129 triazole to enhance π stacking interactions with melanin. 22 The biodistribution study for probes of similar polarity. This observation suggested that a mechanism other than the 151 lipophilicity is guiding clearance, and that retaining the 1,4 triazole core was needed to promote 152 clearance from non-target tissues. 153
Although [
125 I]-7d showed promising biodistribution results, higher uptake in the tumour 154 might be necessary for use as a radiotherapeutic agent. Therefore further derivatization was 155 explored to enhance tumour uptake. We first attempted to alter the electron density of the phenyl 156 group through the use of electron donating and electron withdrawing substituents. The presence 157 of the electron donating groups was expected to increase electron density in the ring and 158 therefore provide a stronger interaction with melanin, which is a known π electron acceptor. 22 
159
The first derivative, [
125 I]-7e, contained two methoxy groups and had a tumour and eye uptake of 160 1.32 and 7.36 %ID/g respectively, at 24 h (Fig. 4) (Fig. 4) there was excellent tumour visualization and low non-specific binding (Fig. 5) , which was 181 consistent with the biodistribution data at 24 h. In addition to the tumour, the eyes were also 182 visible due to the presence of melanin; an observation also in agreement with the biodistribution 183 data and literature reports for other benzamides. tert-Butyl 1-(3,5-dimethoxybenzyl)piperidin-4-ylcarbamate. Following general procedure 232 1, the product was isolated as a white powder (51%, 0.160 g yield). 1 To a solution of Boc protected amine (1 equiv.) in DCM was added TFA (10 equiv.), and the 265 reaction was stirred at room temperature overnight. The reaction mixture was concentrated, 266 dissolved in 10 mL of saturated sodium bicarbonate and extracted three times with 10 mL of 267 DCM (Scheme 2, part 2). The organic layer was dried over Na 2 SO 4 and concentrated to give the 268 desired free amine. 269 
N-(2-(Diethylamino)ethyl)-2-(4-(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl)-1H-1,2,3-300
triazol-1-yl)acetamide. To a solution of 1, the tin TAAG methyl ester (1 equiv.) in methanol (1 301 mL), was added N,N-diethylethylenediamine (3 equiv.) and DIPEA (3 equiv.), and the reaction 302 was heated to 60 °C for 2 h. The reaction mixture was concentrated and purified through column 303 chromatography on silica with 20:1 dichloromethane/methanol. The fractions containing the 304 desired compound were concentrated and the product was isolated as a clear oil (88%, 0.052 g 305 yield). 1 
General Procedure 3: Coupling amines to TAAG (6d-i). 337
To a solution of tin TAAG methyl ester (3) (1 equiv.) in methanol (1 mL) was added amine (1.2 338 equiv.) and DIPEA (3 equiv.), and the reaction was heated to 60 °C for 3 days. The reaction 339 mixture was concentrated and purified through column chromatography on silica with 20:1 340 dichloromethane/methanol. The fractions containing the desired compound were concentrated to 341
give the desired radiolabelling precursor. 342
6d

N-(1-Benzylpiperidin-4-yl)-2-(4-(tributylstannyl)-1H-1,2,3-triazol-1-yl)acetamide. 343
Following general procedure 3, the product was isolated as a white solid (64%, 0.165 g yield). 54 (m, 6H), 1.48 (m, 2H), 1.32 (m, 6H), 1.12 (m, 6H) 
N-(1-(3,5-Dinitrobenzyl)piperidin-4-yl)-2-(4-(tributylstannyl)-1H-1,2,3-triazol-1-361
yl)acetamide. Following general procedure 3, the product was isolated as an orange solid (9%, 362 0.036 g yield). 
N-(1-(2-Fluorobenzyl)piperidin-4-yl)-2-(4-(tributylstannyl)-1H-1,2,3-triazol-1-370
yl)acetamide. Following general procedure 3, the product was isolated as an orange oil (32%, 371 0.056 g yield). 3 . An OS-EM interactive reconstructed method (2 iterations/8 subsets) was used to 461 reconstruct the SPECT data, which was fused to the CT data using in house software. 
